8-methoxy-2-propionamidotetralin | 153811-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 8-methoxy-2-propionamidotetralin
• 英文别名: 8-M-PDOT；N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
• CAS: 153811-33-7
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: RVIGBTUDFAGRTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-methoxy-2-propionamidotetralin 生成 N-((R)-8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propionamide 、 N-((S)-8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propionamide
  参考文献：
  名称：

  Selditz; Copinga; Grol, Pharmazie, 1999, vol. 54, # 3, p. 183 - 191

  摘要：

  DOI：
• 作为产物：
  描述：

  丙酸酐 、 2-氨基-8-甲氧基-1,2,3,4-四氢萘盐酸盐 在 sodium acetate 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 以31%的产率得到8-methoxy-2-propionamidotetralin
  参考文献：
  名称：

  2-Amido-8-methoxytetralins: A series of nonindolic melatonin-like agents

  摘要：

  A series of unsubstituted and methoxy-substituted 2-amidotetralins (4a-q) was prepared and evaluated for their ability to compete for 2-[I-125]iodomelatonin binding to chicken retinal membranes and for their potency to inhibit the calcium-dependent release of [H-3]dopamine from rabbit retina. The lead compound, 2-acetamido-8-methoxytetralin (4j), showed a moderate affinity (K(i) = 46 nM) and potency (IC50 = 1.4 nM) at the melatonin receptor. The structural requirements necessary for optimal agonistic activity at the melatonin receptor are as follows. First, the amido group, which should have a small, nonbranched alkyl group, is essential for affinity, and second, the methoxy substituent at the 8-position of the 2-amidotetralin ring is essential for optimal agonistic activity at the melatonin receptor. We concluded that this series of unsubstituted and methoxy-substituted 2-amidotetralins constitutes a class of nonindolic melatonin-like agents that can be used as pharmacological tools to further characterize melatonin receptors and to elucidate the mode of action of melatonin.

  DOI：

  10.1021/jm00072a008

文献信息

• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• Substituted 2-amidotetralins as melatonin agonists and antagonists
  申请人：NORTHWESTERN UNIVERSITY

  公开号：EP0420064A2

  公开（公告）日：1991-04-03

  The present invention relates generally to compounds having melatonin receptor activities and in particular to substituted 2-amidotetralin derivatives; to pharmaceutical preparations comprising such compounds; and to methods for using these compounds as therapeutic and diagnostic reagents.

  本发明一般涉及具有褪黑激素受体活性的化合物，特别是取代的 2-脒基四氢萘衍生物；涉及包含这些化合物的药物制剂；以及涉及将这些化合物用作治疗和诊断试剂的方法。
• DETERMINING A CIRCADIAN RHYTHM
  申请人：Vanda Pharmaceuticals Inc.

  公开号：EP3620794A1

  公开（公告）日：2020-03-11

  Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

  本发明的实施方案涉及使用褪黑激素激动剂治疗患者（包括光感受损患者，如盲人患者）的自由运行昼夜节律，以及测量昼夜节律的方法。
• Treatment of circadian rhythm disorders
  申请人：Vanda Pharmaceuticals Inc.

  公开号：US10449176B2

  公开（公告）日：2019-10-22

  Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

  本发明的实施方案涉及使用褪黑激素激动剂治疗患者（包括光感受损患者，如盲人患者）的自由运行昼夜节律，以及测量昼夜节律的方法。
• Melatonin combination therapy for improving sleep quality
  申请人：Barberich J. Timothy

  公开号：US20050164987A1

  公开（公告）日：2005-07-28

  One aspect of the present invention relates to pharmaceutical compositions comprising a sedative agent; and melatonin or a melatonin analog, collectively referred to as “melatonin agents.” In a preferred embodiment, the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention also relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.

  本发明的一个方面涉及包含镇静剂、褪黑素或褪黑素类似物的药物组合物，统称为 "褪黑素制剂"。在一个优选的实施方案中，镇静剂是艾佐匹克隆。本发明的药物组合物可用于治疗各种睡眠障碍。此外，本发明还涉及一种治疗睡眠异常或失眠症患者的方法，包括施用治疗有效量的本发明药物组合物。